SCHEMBL2448726

SCHEMBL2448726

Cc1cc(C)n(-c2nc(Cl)cc(Nc3ccc(Cl)cc3)n2)n1

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TP53 P04637 4/20 0.65
LMNA P02545 3/20 0.63
KCNN3 Q9UGI6 3/20 0.62
POLB P06746 4/20 0.62
BCL6 P41182 1/20 0.62
HTT P42858 1/20 0.60
NPSR1 Q6W5P4 2/20 0.60
HIF1A Q16665 1/20 0.60
MAPT P10636 2/20 0.57
ALOX15 P16050 3/20 0.56
TSHR P16473 1/20 0.56
MAPK1 P28482 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
KCNN2 Q9H2S1 1/20 0.55
USP2 O75604 1/20 0.53
PTPN7 P35236 1/20 0.53
CREBBP Q92793 1/20 0.53
TDP1 Q9NUW8 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4212917 0.90 TP53 (0.80) TP53LMNAKCNN3POLBBCL6
SCHEMBL19690859 0.87 KCNN3 (0.71) TP53LMNAKCNN3POLBHTT
SCHEMBL4210667 0.85 BCL6 (0.64) TP53LMNAKCNN3POLBBCL6
SCHEMBL3092078 0.81 HTT (0.63) TP53LMNAKCNN3POLBHTT
SCHEMBL19700500 0.80 TP53 (0.58) TP53LMNAKCNN3POLBBCL6
SCHEMBL19700501 0.80 TP53 (0.58) TP53LMNAKCNN3POLBBCL6
SCHEMBL19700496 0.80 TP53 (0.58) TP53LMNAKCNN3POLBBCL6
SCHEMBL2447803 0.79 ADORA2A (0.66) TP53LMNAKCNN3POLBHTT
SCHEMBL4215477 0.79 TP53 (1.00) TP53LMNAKCNN3POLBHTT
SCHEMBL1936057 0.79 HTT (0.86) TP53LMNAKCNN3POLBBCL6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170355708-A1 POTASSIUM CHANNEL MODULATORS CADENT THERAPEUTICS, INC. 2017-12-14 US disclosed
US-20170355708-A1 POTASSIUM CHANNEL MODULATORS CADENT THERAPEUTICS, INC. 2017-12-14 US disclosed
US-20170355708-A1 POTASSIUM CHANNEL MODULATORS CADENT THERAPEUTICS, INC. 2017-12-14 US disclosed
US-8618099-B2 Pyrazolyl-pyrimidine derivatives and their use as potassium channel modulators ATAXION, INC. (US) 2013-12-31 US disclosed
US-20110230484-A1 PYRAZOLYL-PYRIMIDINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2011-09-22 US disclosed
US-20110230484-A1 PYRAZOLYL-PYRIMIDINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2011-09-22 US disclosed
US-20110230484-A1 PYRAZOLYL-PYRIMIDINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2011-09-22 US disclosed
CN-102177154-A Pyrazolyl-pyrimidine derivatives and their use as potassium channel modulators NEUROSEARCH AS 2011-09-07 CN disclosed
WO-2010026087-A1 PYRAZOLYL-PYRIMIDINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230484-A1 PYRAZOLYL-PYRIMIDINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS KCNJ2, KCNJ4, KCNN2 TP53 3358/4885LMNA 2636/4885KCNN3 5/4885
US-20170355708-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 TP53 4484/4885LMNA 1523/4885KCNN3 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.